Advanced

Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.

Zinman, Bernard; Ahrén, Bo LU ; Neubacher, Dietmar; Patel, Sanjay; Woerle, Hans-Juergen and Johansen, Odd Erik (2016) In Canadian Journal of Diabetes 40(1). p.50-57
Abstract
With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl peptidase-4 inhibitor linagliptin as add-on to insulin in patients with type 2 diabetes.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Canadian Journal of Diabetes
volume
40
issue
1
pages
50 - 57
publisher
Elsevier
external identifiers
  • pmid:26474870
  • wos:000369170800011
  • scopus:84951036117
ISSN
2352-3840
DOI
10.1016/j.jcjd.2015.06.010
language
English
LU publication?
yes
id
5edf55df-2491-44a9-8d39-f6638d3233a1 (old id 8149135)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26474870?dopt=Abstract
date added to LUP
2015-11-03 15:39:00
date last changed
2017-10-22 03:27:01
@article{5edf55df-2491-44a9-8d39-f6638d3233a1,
  abstract     = {With the expanding armamentarium of noninsulin therapies for type 2 diabetes mellitus, the use of insulin with various oral agents is becoming more common. In this study, we assessed the efficacy and cardiovascular (CV) safety of the dipeptidyl peptidase-4 inhibitor linagliptin as add-on to insulin in patients with type 2 diabetes.},
  author       = {Zinman, Bernard and Ahrén, Bo and Neubacher, Dietmar and Patel, Sanjay and Woerle, Hans-Juergen and Johansen, Odd Erik},
  issn         = {2352-3840},
  language     = {eng},
  number       = {1},
  pages        = {50--57},
  publisher    = {Elsevier},
  series       = {Canadian Journal of Diabetes},
  title        = {Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.},
  url          = {http://dx.doi.org/10.1016/j.jcjd.2015.06.010},
  volume       = {40},
  year         = {2016},
}